H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 30.4 DKK 4.65% Market Closed
Market Cap: 30.3B DKK

Relative Value

The Relative Value of one HLUN A stock under the Base Case scenario is 45.45 DKK. Compared to the current market price of 30.4 DKK, H Lundbeck A/S is Undervalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HLUN A Relative Value
Base Case
45.45 DKK
Undervaluation 33%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
48
vs Industry
61
Median 3Y
1.3
Median 5Y
1.3
Industry
2.4
Forward
1.2
vs History
48
vs Industry
38
Median 3Y
8.8
Median 5Y
8.8
Industry
20.9
vs History
5
vs Industry
39
Median 3Y
5
Median 5Y
5
Industry
15.9
vs History
45
vs Industry
36
Median 3Y
2.1
Median 5Y
2.1
Industry
23.7
vs History
67
vs Industry
53
Median 3Y
1.3
Median 5Y
1.3
Industry
2
vs History
10
vs Industry
50
Median 3Y
1.4
Median 5Y
1.4
Industry
2.6
Forward
1.7
vs History
10
vs Industry
65
Median 3Y
1.8
Median 5Y
1.8
Industry
5
vs History
27
vs Industry
40
Median 3Y
5.1
Median 5Y
5.1
Industry
12.4
Forward
6.7
vs History
40
vs Industry
37
Median 3Y
7.6
Median 5Y
7.6
Industry
15.9
vs History
2
vs Industry
31
Median 3Y
5
Median 5Y
5
Industry
14.2
vs History
8
vs Industry
25
Median 3Y
6
Median 5Y
6
Industry
17.6
vs History
67
vs Industry
60
Median 3Y
1
Median 5Y
1
Industry
1.8

Multiples Across Competitors

HLUN A Competitors Multiples
H Lundbeck A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
H Lundbeck A/S
CSE:HLUN A
30.1B DKK 1.3 9.2 8 8
US
Eli Lilly and Co
NYSE:LLY
717.8B USD 14.6 64.6 34.8 38
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
364B USD 4.1 16.7 12.2 16
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.5 18.8 12.4 14.1
CH
Roche Holding AG
SIX:ROG
206.6B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
179.2B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
160.2B GBP 3.9 27.4 130.4 196.7
US
Merck & Co Inc
NYSE:MRK
191.4B USD 3 11 8.2 10
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
129.8B USD 2.1 16.5 7.2 10.1
P/E Multiple
Earnings Growth PEG
DK
H Lundbeck A/S
CSE:HLUN A
Average P/E: 22.9
9.2
21%
0.4
US
Eli Lilly and Co
NYSE:LLY
64.6
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.7
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.8
18%
1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.4
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11
17%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.5
30%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
H Lundbeck A/S
CSE:HLUN A
Average EV/EBITDA: 394.6
8
4%
2
US
Eli Lilly and Co
NYSE:LLY
34.8
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.2
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.4
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.4
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
H Lundbeck A/S
CSE:HLUN A
Average EV/EBIT: 1 697.7
8
4%
2
US
Eli Lilly and Co
NYSE:LLY
38
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
14%
1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.7
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1